http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#Head
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#assertion
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#provenance
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#pubinfo
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#assertion
http://purl.obolibrary.org/obo/DOID_7147
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_7147
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00065
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
http://www.w3.org/2000/01/rdf-schema#label
renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00065
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#provenance
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#pubinfo
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#sig
http://purl.org/nanopub/x/hasSignature
EdCwIo58/Mc3AXoKMCqr6ggtXKKtYDeHpx6bRvRJhRjZrhRGdYDWvIBgYBunKxsJl8IuNWESJfRXBaSHbT2KlZDisyBSAhZGbxusuZcamIwIX0IAjgNzsXHrhmMYwuLKBfXg0EaYAlbGsSYgL42qIXJyBj6ChwwaHNLQBciGnmo=
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://purl.org/dc/terms/created
2021-07-03T15:18:05.125+02:00
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAAfNwyKVhSBJzOFxfgZL--xGlxfcIq3K0rC5qNfQ-CJo
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs